A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial

Salvatorelli, Nicola; García-Larrosa, Alejandro; Allegrini, Alessandro; Pavone, Daniele

doi:10.1159/000445326

Cited by 13 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 6 months, symptomatic recurrence among patients treated with the medical device was reduced by 19.4% in comparison with the placebo group ( p = 0.015). The number of micturitions among patients treated with the medical device was significantly reduced, in comparison with the placebo group, at Day 3 and 20 [ 27 ].…”

Section: Clinical Studies With Mucosal Protectors In Urinary Tractmentioning

confidence: 99%

“…These favourable in vitro results have been correlated with favourable results in clinical trials in patients with gastroenteritis [ 23 , 24 ], nasal disorders [ 15 ] and dry eye syndrome [ 28 ]. Similar mucosal protectors containing reticulated proteins have also proved to be useful for the treatment of IBS [ 48 ] and UTIs [ 26 , 27 ]. Based on the similar film-forming protective effects between xyloglucan and other mucosal protectors, medical devices containing xyloglucan can also be expected to have a role in IBS and UTIs, although randomized clinical trials should be performed to demonstrate this.…”

Section: Concluding Remarks and Future Perspectivesmentioning

confidence: 99%

“…We present the results of in vitro studies in models of intestinal and nasal mucosa and conjunctival cells [ 1 , 16 , 17 , 22 ] and in vivo models of intestinal inflammation and diarrhoea, demonstrating its barrier properties against bacterial adhesion and invasion and pro-inflammatory compounds, and the results of clinical studies in which the mucosal protectors have demonstrated their protective effect in patients with gastrointestinal disorders (mainly diarrhoea), urinary tract infections, nasal respiratory diseases and dry eye syndrome [ 15 , 23 , 24 , 25 , 26 , 27 , 28 ]. Since medical devices containing mucosal protectors are a new strategy for the management of these diseases, we discuss the data published to date and the issues that deserve further research.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Piqué

Gómez‐Guillén

Montero

2018

IJMS

View full text Add to dashboard Cite

Disruption of the epithelial barrier function has been recently associated with a variety of diseases, mainly at intestinal level, but also affecting the respiratory epithelium and other mucosal barriers. Non-pharmacological approaches such as xyloglucan, with demonstrated protective barrier properties, are proposed as new alternatives for the management of a wide range of diseases, for which mucosal disruption and, particularly, tight junction alterations, is a common characteristic. Xyloglucan, a natural polysaccharide derived from tamarind seeds, possesses a “mucin-like” molecular structure that confers mucoadhesive properties, allowing xyloglucan formulations to act as a barrier capable of reducing bacterial adherence and invasion and to preserve tight junctions and paracellular flux, as observed in different in vitro and in vivo studies. In clinical trials, xyloglucan has been seen to reduce symptoms of gastroenteritis in adults and children, nasal disorders and dry eye syndrome. Similar mucosal protectors containing reticulated proteins have also been useful for the treatment of irritable bowel syndrome and urinary tract infections. The role of xyloglucan in other disorders with mucosal disruption, such as dermatological or other infectious diseases, deserves further research. In conclusion, xyloglucan, endowed with film-forming protective barrier properties, is a safe non-pharmacological alternative for the management of different diseases, such as gastrointestinal and nasal disorders.

show abstract

Section: Clinical Studies With Mucosal Protectors In Urinary Tractmentioning

confidence: 99%

Section: Concluding Remarks and Future Perspectivesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Piqué

Gómez‐Guillén

Montero

2018

IJMS

View full text Add to dashboard Cite

show abstract

“…In the field of GE and UTI treatments, non-pharmacological oral supplements, including cranberry proanthocyanidins [ 13 , 14 , 15 ], probiotics [ 16 ], and mucosal protectors (such as xyloglucan) have been evaluated for the protection against these two diseases [ 17 , 18 ]. Xyloglucan belongs to a new class of products; it is extracted from the seeds of the tamarind tree ( Tamarindus indica ) and is defined as “mucosal protectors” which form a bio protective film, restoring the physiological functions of the intestinal walls.…”

Section: Introductionmentioning

confidence: 99%

Protective Effects of Xyloglucan in Association with the Polysaccharide Gelose in an Experimental Model of Gastroenteritis and Urinary Tract Infections

Esposito

Campolo

Casili

et al. 2018

IJMS

View full text Add to dashboard Cite

Acute infectious gastroenteritis (GE) and urinary tract infection (UTI) are common diseases and are normally perceived as mild and limiting illnesses. Xyloglucan is a natural plant polymer with protective barrier properties, also known as “mucosal protectors”, which is the main ingredient of medical devices developed for the management of different diseases, such as gastrointestinal diseases, urinary tract infections, or respiratory allergic diseases. The aim of this study was to evaluate the protective effect of xyloglucan in association with gelose (also called agar) in an experimental model of bacterial GE and UTI in rats. Two kinds of infection were induced by oral administration of Salmonella enterica and Enterococcus hirae for three days. Two days before the bacterial administration, preventive oral treatment with xyloglucan + gelose (10 mg/kg + 5 mg/kg) was performed daily until the seventh day. Twenty-four hours after the last treatment, rats were sacrificed and urinary tracts and intestines for different analysis were collected. The results showed that xyloglucan plus gelose was able to reduce intestinal morphological changes (p < 0.05 for both), tight junctions (TJ) permeability (p < 0.001 for both), and neutrophil infiltration (p < 0.05 for both) induced by bacterial infections, highlighting its barrier proprieties. Moreover, the compound reduced the number of bacterial colonies in the urinary tract favoring elimination by feces. The results obtained in the present study suggest that the protective barrier properties of xyloglucan plus gelose allow the prevention of GE and UTI in models of infections in rats.

show abstract

“…Xyloglucan is a natural hemicellulose extracted from the seeds of the tamarind tree ( Tamarindus indica ), which forms a bio-protective film. In in vitro and in vivo studies, we have demonstrated the barrier properties of xyloglucan, avoiding the contact with pathogenic bacteria and bacterial products, being currently used as alternative non-pharmacological alternatives in intestinal and urinary tract alterations [ 21 – 25 ].…”

Section: Introductionmentioning

confidence: 99%

Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study

Servi¹,

Ranzini²,

Piqué

2017

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

BackgroundTo evaluate barrier protective properties of Rhinosectan® spray, a medical device containing xyloglucan, on nasal epithelial cells (MucilAir).MethodsMucilAir-Nasal, a three-dimensional organotypic (with different cell types) airway tissue model, was treated with the medical device Rhinosectan® (30 µL) or with controls (Rhinocort—budesonide—or saline solution). The protective barrier effects of Rhinosectan® were evaluated by: TEER (trans-epithelial electrical resistance) (preservation of tight junctions), Lucifer Yellow assay (preservation of paracellular flux) and confocal immunofluorescence microscopy (localization of tight junction proteins).ResultsExposure of MucilAir with Rhinosectan® protected cell tight junctions (increases in TEER of 13.1% vs −6.3% with saline solution after 1 h of exposure), and preserved the paracellular flux, even after exposure with pro-inflammatory compounds (TNF-α and LPS from Pseudomonas aeruginosa 10). Results of confocal immunofluorescence microscopy demonstrated that, after treatment with the pro-inflammatory mixture, Rhinosectan® produced a slight relocation of zona occludens-1 in the cytosol compartment (while Rhinocort induced expression of zona-occludens-1), maintaining the localization of occludin (similarly to negative control).ConclusionsResults of our study indicates that Rhinosectan® creates a protective physical barrier on nasal epithelial cells in vitro, allowing the avoidance of allergens and triggering factors, thus confirming the utility of this medical device in the management of nasal respiratory diseases, as rhinitis or rhinosinusitis.

show abstract

A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial

Cited by 13 publications

References 17 publications

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Protective Effects of Xyloglucan in Association with the Polysaccharide Gelose in an Experimental Model of Gastroenteritis and Urinary Tract Infections

Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study

Contact Info

Product

Resources

About